SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EARNINGS ARTICLE H impact

Novartis Expects 5% Net Sales CAGR At Constant Currencies Through 2031, Core Operating Margin Above 40% By 2029

Raises Peak Sales Guidance To $8B Each For Kesimpta And Rhapsido/Remibrutinib, $5B For Scemblix - Ten Late-Stage Pipeline Assets Have Multi-Billion-Dollar Peak Sales Guidance - Expects More Than 35 Submission-Enabling Readouts Through 2031 - Projects Sustained Mid-Single-Digit Sales Growth Over Long Term

Raises Peak Sales Guidance To $8B Each For Kesimpta And Rhapsido/Remibrutinib, $5B For Scemblix - Ten Late-Stage Pipeline Assets Have Multi-Billion-Dollar Peak Sales Guidance - Expects More Than 35 Submission-Enabling Readouts Through 2031 - Projects Sustained Mid-Single-Digit Sales Growth Over Long Term

Related stories